Related references
Note: Only part of the references are listed.Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease
Peter A. LeWitt et al.
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY (2018)
PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats
Michael Aagaard Andersen et al.
TOXICOLOGY (2018)
LRRK2 activation in idiopathic Parkinson's disease
Roberto Di Maio et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity
Jack D. Scott et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci
Diana Chang et al.
NATURE GENETICS (2017)
Parkinson disease
Werner Poewe et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
LRRK2 levels in immune cells are increased in Parkinson'sdisease
D. A. Cook et al.
NPJ PARKINSONS DISEASE (2017)
Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases
Martin Steger et al.
ELIFE (2016)
Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
Reina N. Fuji et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibitions
Matthew J. Fell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Discovery of Highly Potent, Selective, and Brain-Penetrant Aminopyrazole Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors
Anthony A. Estrada et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease
Mike A. Nalls et al.
NATURE GENETICS (2014)
Surfactant Secretion in LRRK2 Knock-Out Rats: Changes in Lamellar Body Morphology and Rate of Exocytosis
Pika Miklavc et al.
PLOS ONE (2014)
Di-22:6-bis(monoacylglycerol)phosphate: A clinical biomarker of drug-induced phospholipidosis for drug development and safety assessment
Nanjun Liu et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2014)
The Genetics of Parkinson's Disease: Progress and Therapeutic Implications
Andrew B. Singleton et al.
MOVEMENT DISORDERS (2013)
The current and projected economic burden of Parkinson's disease in the United States
Stacey L. Kowal et al.
MOVEMENT DISORDERS (2013)
Leucine-Rich Repeat Kinase 2 (LRRK2)-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis
Daniel Ness et al.
PLOS ONE (2013)
Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs
Marco A. S. Baptista et al.
PLOS ONE (2013)
Discovery of Highly Potent, Selective, and Brain-Penetrable Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors
Anthony A. Estrada et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway
Youren Tong et al.
MOLECULAR NEURODEGENERATION (2012)
LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice
Martin C. Herzig et al.
HUMAN MOLECULAR GENETICS (2011)
Biological Function of the Cellular Lipid BMP-BMP as a Key Activator for Cholesterol Sorting and Membrane Digestion
Hichem D. Gallala et al.
NEUROCHEMICAL RESEARCH (2011)
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization
Nicolas Dzamko et al.
BIOCHEMICAL JOURNAL (2010)
Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities
Elizabeth A. Tengstrand et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Effect of lysosomal storage on bis(monoacylglycero)phosphate
Peter J. Meikle et al.
BIOCHEMICAL JOURNAL (2008)
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
Daniel G. Healy et al.
LANCET NEUROLOGY (2008)
Regulation of surfactant secretion in alveolar type II cells
Alexandra V. Andreeva et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2007)
Kinase activity of mutant LRRK2 mediates neuronal toxicity
Wanli W. Smith et al.
NATURE NEUROSCIENCE (2006)
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
Elisa Greggio et al.
NEUROBIOLOGY OF DISEASE (2006)
Share Paper
